ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

VTRS Viatris Inc

10.05
-0.06 (-0.59%)
Jun 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,445,450
Bid Price 10.01
Ask Price 10.06
News -
Day High 10.25

Low
8.74

52 Week Range

High
13.6175

Day Low 9.925
Share Name Share Symbol Market Stock Type
Viatris Inc VTRS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.06 -0.59% 10.05 19:00:00
Open Price Low Price High Price Close Price Previous Close
10.10 9.925 10.25 10.05 10.11
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
36,539 6,445,450 US$ 10.06 US$ 64,853,441 - 8.74 - 13.6175
Last Trade Type Quantity Price Currency
18:53:11 37 US$ 10.05 USD

Viatris (VTRS) Options Flow Summary

Overall Flow

Bullish

Net Premium

34k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Viatris Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
11.94B 1.19B - 15.43B 54.7M 0.05 218.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Viatris News

Date Time Source News Article
6/07/202405:59PR Newswire (US)Viatris to Report Second Quarter 2024 Financial Results on..
6/04/202405:59PR Newswire (US)Viatris to Participate in the Goldman Sachs 45th Annual..
6/03/202406:16Edgar (US Regulatory)Form 8-K - Current report
6/03/202405:59PR Newswire (US)Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of..
5/31/202405:59PR Newswire (US)Viatris to Participate in the Jeffries Global Healthcare..
5/28/202417:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/28/202415:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
5/21/202405:59PR Newswire (US)Viatris Publishes 2023 Sustainability Report: Building..
5/09/202406:47IH Market NewsU.S. Index Futures Dip, Bank of England Holds Interest Rates..
5/09/202406:44Edgar (US Regulatory)Form 8-K - Current report
5/09/202405:59PR Newswire (US)Viatris Reports Strong First Quarter 2024 Financial Results..
5/02/202416:00PR Newswire (US)Viatris to Participate in the BofA Securities 2024 Health..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VTRS Message Board. Create One! See More Posts on VTRS Message Board See More Message Board Posts

Historical VTRS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week10.4610.949.92510.419,554,329-0.41-3.92%
1 Month11.0411.089.92510.507,340,658-0.99-8.97%
3 Months11.8812.2159.92511.187,732,794-1.83-15.40%
6 Months10.3013.61759.92511.668,952,101-0.25-2.43%
1 Year10.2013.61758.7410.818,832,532-0.15-1.47%
3 Years14.63515.608.4211.259,689,730-4.59-31.33%
5 Years16.4618.868.4212.139,959,081-6.41-38.94%

Viatris Description

We are Viatris. A new kind of global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines advance sustainable operations develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway. Formed in November 2020 we bring together scientific manufacturing and distribution expertise with proven regulatory medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. At Viatris our portfolio comprises more than 1400 approved molecules across a wide range of therapeutic areas spanning both non-communicable and infectious diseases including globally recognized brands complex generic and branded medicines and a growing portfolio of biosimilars.